Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.

Abstract

Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-alpha, IFN-beta) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-beta and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-beta for the treatment of SARS.

Statistics

051015'04'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

53 Citations

Semantic Scholar estimates that this publication has 53 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Morgenstern2005RibavirinAI, title={Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.}, author={Birgit Morgenstern and Martin Michaelis and Patrick Carolus Baer and Hans Wilhelm Doerr and Jindrich Cinatl}, journal={Biochemical and biophysical research communications}, year={2005}, volume={326 4}, pages={905-8} }